Jörn Drappa has served as a member of Alpine’s Board of Directors since July 2022. Dr. Drappa most recently served as Chief Medical Officer of Ventyx Biosciences. Prior to Ventyx, Dr. Drappa co-founded Viela Bio, a biotechnology company focused on the discovery, development and commercialization of treatments for autoimmune and severe inflammatory diseases and served as its Head of R&D and Chief Medical Officer through its acquisition by Horizon Therapeutics in March 2021 for $3.1 billion. At Viela Bio, Dr. Drappa led the development of UPLIZNA™ (inebilizumab-cdon) in multiple indications, culminating in its approval for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD). Prior to Viela Bio, he held various roles of increasing responsibility leading clinical development programs at MedImmune/AstraZeneca, Genentech/Roche, and Amgen.

Dr. Drappa received his medical and Ph.D. degrees from the University of Cologne in Germany. He completed a residency in internal medicine at New York Presbyterian Hospital and a fellowship in rheumatology at the Hospital for Special Surgery, NY.